Iadademstat (LSD1 inhibitor)

Current understanding

To be populated as evidence accumulates.

2026-04-02 — Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: cross-connection with seclidemstat-azacitidine-mds-cmml: Both seclidemstat and iadademstat are LSD1/KDM1A inhibitors being combined with hypomethylating agents (azacitidine and decitabine/ASTX727 respectively) in myeloid neoplasms — parallel clinical strategies. (novelty: 3)
2026-04-28 — A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs): Phase II randomized trial (trial-early) testing iadademstat added to ASTX727 in accelerated/blast phase Ph-negative MPNs — first-in-class LSD1 inhibitor + oral HMA combination for advanced MPN. (novelty: 4)